Bravecto 1 Month is a drug owned by INTERVET, INC. It is protected by 9 US drug patents filed from 2025 to 2035. Out of these, 4 patents are active and 5 patents have expired. Details of Bravecto 1 Month’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US9173870 | 22 Dec, 2031 | Active |
| US7662972 | 28 Jun, 2027 | Active |
| US8022089 | 04 Mar, 2025 | Expired |
| US10045969 | 04 Mar, 2025 | Expired |
| US10874645 | 04 Mar, 2025 | Expired |
| US10596157 | 04 Mar, 2025 | Expired |
| US8492311 | 04 Mar, 2025 | Expired |
Exclusivity Information
Bravecto 1 Month holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Bravecto 1 Month's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Nov 25, 2027 |
About Bravecto 1 Month
Bravecto 1 Month is a drug
owned by INTERVET, INC.
Bravecto 1 Month uses
Fluralaner as the active
ingredient.
Active Ingredient:
Bravecto 1 Month uses
Fluralaner as the active ingredient.
Check out other Drugs and Companies using
Fluralaner ingredient.